Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies

por Toth, Peter P., Jones, Steven R., Monsalvo, Maria Laura, Elliott‐Davey, Mary, López, J. Antonio G., Banach, Maciej
Publicado 2020

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study

por Rosenson, Robert S., Daviglus, Martha L., Handelsman, Yehuda, Pozzilli, Paolo, Bays, Harold, Monsalvo, Maria Laura, Elliott-Davey, Mary, Somaratne, Ransi, Reaven, Peter
Publicado 2019